Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response

Jessica B. Foster,^{1,2,*} Namrata Choudhari,^{3,4,†} Jessica Perazzelli,¹ Julie Storm,¹ Ted J. Hofmann,¹ Payal Jain,^{3,4} Phillip B. Storm,^{2–5} Norbert Pardi,⁶ Drew Weissman,⁶ Angela J. Waanders,^{1,2,4} Stephan A. Grupp,^{1,2} Katalin Karikó,⁷ Adam C. Resnick,^{2–4,8,‡} and David M. Barrett^{1,2,‡}

Divisions of ¹Oncology and ³Neurosurgery, Centers for ²Childhood Cancer Research and ⁴Data-Driven Discovery in Biomedicine,

and ⁸Department of Biomedical and Health Informatics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania;

⁵Department of Neurosurgery and ⁶Division of Infectious Diseases, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; and ⁷BioNTech RNA Pharmaceuticals, Mainz, Germany.

[†]These authors contributed equally to this work.

[‡]These authors jointly supervised this work.

T cells made with messenger RNA (mRNA) encoding chimeric antigen receptor (CAR) offer a safe alternative to those transduced with viral CARs by mitigating the side effects of constitutively active T cells. Previous studies have shown that mRNA CAR T cells are transiently effective but lack persistence and potency across tumor types. It was hypothesized that the efficacy of mRNA CARs could be improved by utilizing recent advancements in RNA technology, such as incorporating a modified nucleoside, 1-methylpseudouridine, into the mRNA and applying a novel purification method using RNase III to eliminate dsRNA contaminants. T cells electroporated with nucleoside-modified and purified mRNA encoding CD19 CAR showed an initial twofold increase in CAR surface expression, as well as a twofold improvement in cytotoxic killing of leukemia cells that persisted up to 5 days. T cells generated with nucleoside-modified and purified CAR mRNA also showed reduced expression of checkpoint regulators and a differential pattern of genetic activation compared to those made with conventional mRNA. *In vivo* studies using a leukemia mouse model revealed that the most robust 100-fold suppression of leukemic burden was achieved using T cells electroporated with purified mRNAs, regardless of their nucleoside modification. The results provide a novel approach to generate mRNA for clinical trials, and poise mRNA CAR T cells for increased efficacy during testing as new CAR targets emerge.

Keywords: RNA, chimeric antigen receptor, T cell, immunotherapy

INTRODUCTION

HARNESSING A PATIENT'S own immune system to combat cancer is now possible due to huge strides emerging in the field of immunotherapy over the last decade. One of the most promising advances utilizes chimeric antigen receptors (CARs), a cancer therapeutic that combines the specificity of an antibody with the antitumor immune activity of T cells. CARs are designed to recognize a specific tumor antigen in their receptor domain and are

linked to T cell receptor-activating domains intracellularly.^{1,2} This model allows for CAR T cells to overcome the immune escape normally occurring in various malignancies.³ CAR T cell therapy has demonstrated tremendous success for hematologic malignancies, both in preclinical studies⁴ and in clinical trials,^{5–7} with numerous new trials emerging in recent years. Despite its effectiveness in hematologic malignancies, there has been only modest success when used to target solid tumors.^{8–11}

*Correspondence: Dr. Jessica Foster, The Children's Hospital of Philadelphia, 3501 Civic Center Blvd, CTRB Room 3052, Philadelphia, PA 19104. E-mail: fosterjb@email.chop.edu

© Jessica B. Foster et al. 2018; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are cited.

One drawback of current CAR technology is that gene transfer into human T cells has primarily relied on a viral- or transposon-based vector. While this approach has proven successful, it also has several limitations due to the permanent genetic modification of the cells. These include the risk of insertional mutagenesis, as has been seen in trials for severe combined immunodeficiency and Wiskott–Aldrich syndrome using retroviral vectors in hematopoietic stem cells,^{12,13} a time-consuming and expensive viral manufacture process difficult for iterative trials that incorporate evolving CAR design innovations,¹⁴ and perhaps most importantly, the risk of persistent untoward side effects. The most often-reported side effect is cytokine release syndrome (CRS), which results from over-activation of the T cells and subsequent bystander activation of the innate immune system with increased cytokine production.^{15–17} CRS can be fatal, such as in the recent reports of cerebral edema.¹⁸ In addition to CRS, severe side effects and death have also resulted from on-target off-tumor antigens of healthy cells that are being attacked by the constitutively active T cells.^{19–23} This last concern is particularly important, as many target antigens are not unique to the tumor itself.

To avoid viral vectors, several recent studies have used mRNA electroporation to express CAR molecules on T cells transiently, which has been successful in demonstrating antitumor activity.^{24–28} *In vitro*-transcribed (IVT) mRNA encoding CAR (mRNA CAR) offers a cost- and time-effective alternative to retroviral constructs, and its transient nature allows for dose escalation by multiple injections, without the risk of permanent T-cell activity. Mouse xenograft models of leukemia have been successfully treated with mRNA CAR therapy.^{14,28} However, for solid tumors, there has been difficulty penetrating into the tumor, as the T cells become exhausted quickly and show limited ability to proliferate in the tumor microenvironment.^{26,29,30} Despite these difficulties, clinical trials are currently underway utilizing mRNA CAR T cells, as their safety profile makes them the most attractive option for immunotherapy when side effects are unknown or pose a potential danger. Thus, mRNA CAR T cells need to be improved to enhance their ability for tumor penetration and cytotoxicity, as well as showing efficacy to give a reasonable estimate of target-specific toxicity.

Recent advancement of *in vitro* mRNA technology demonstrates strategies that can improve the translatability and stability of IVT mRNA,³¹ which it was hypothesized would ultimately improve the antitumor activity of CAR T cells generated with mRNA.

Naturally occurring modified nucleosides, such as pseudouridine (Ψ) and 1-methylpseudouridine (m1 Ψ), allow the transfected mRNA to avoid immune stimulation and increase mRNA stability, leading to enhanced translational capacity.^{32–34} RNA purification to remove contaminating double-stranded RNA (dsRNA), which normally stalls translation, has been shown to result in further improvements, thus achieving maximal translation for longer duration.^{35,36} The objective of this study was to combine these techniques to generate a more stable mRNA product, which would allow for a superior mRNA CAR T cell.

METHODS

Generation of CAR constructs and mRNA

DNA of a third-generation CAR containing a scFv domain directed against CD19 linked to CD3 ζ and 4-1BB intracellular signaling domains was generated, as previously described.^{14,37} The CD19 CAR DNA was linearized, and then a MEGAscript T7 RNA transcription kit was used to synthesize the RNA. Four different mRNA isolates were generated. To synthesize the mRNA for the first group, the transcription reaction was supplemented with m1 Ψ triphosphate (Trilink) in place of UTP. For the second group, the m1 Ψ -containing mRNAs were purified by digesting with ribonuclease III (RNase III) (Epicentre), as described below. For the third group, mRNA was transcribed in the presence of UTP using standard methods followed by RNase III digestion. Finally, control mRNA was transcribed in the presence of UTP using standard methods without RNase III purification. MEGAscript T7 RNA transcription kit (Ambion, Thermo Fisher Scientific) was used to generate all RNA. To contain cap1, all mRNA was enzymatically capped with guanylyl-transferase and 2'-O-methyltransferase (CellScript), and long polyadenylate tail was added using poly(A) polymerase (CellScript), according to protocols previously described.³⁸ RNA purification with RNase III for the two purified experimental arms was completed before capping and poly(A) tailing, using a protocol described below.

Purification of IVT mRNA using RNase III

To digest dsRNA contaminants present in the IVT mRNA sample, an aliquot of 2.5 μ L of RNase III (Epicentre) diluted to 0.01 IU/ μ L in reaction buffer (33 mM of Tris, pH 8.0, 200 mM of potassium acetate, and 1 mM of magnesium acetate) was combined with 100 μ g of mRNA in a final volume of 125 μ L of reaction buffer and incubated at 37°C for 30 min.³⁹ Following a phenol-chloroform (pH 4.5; Thermo Fisher Scientific) and two chloroform ex-

tractions, the mRNA was precipitated from the aqueous phase by adding one tenth volume of 3 M sodium acetate, pH 5.5, and an equal volume of isopropanol. The centrifuged pellet was reconstituted in water and stored at -20°C . Verification of removal of dsRNA was completed using immunoblot assay, as previously described³⁵ and shown in Supplementary Fig. S1.

T-cell expansion and RNA electroporation

Human T cells were collected from de-identified healthy donors by the University of Pennsylvania Human Immunology Core and then stimulated with CD3/CD28 microbeads (Gibco), as previously described.³⁷ Stimulated and rested T cells were resuspended at 5×10^6 cells in $100 \mu\text{L}$ of nucleofector reagent from the Nucleofector T-cell transfection kit (Lonza) prior to adding $10 \mu\text{g}$ of mRNA for electroporation. For *in vitro* studies, mRNA electroporation was performed using the Amaxa program T23 (Lonza). For *in vivo* studies, stimulated and rested T cells were electroporated with mRNA using ECM 830 Square Wave Electroporation System (BTX).

In vitro studies

A Nalm-6 leukemia cell line (obtained from DSMZ) permanently expressing firefly luciferase⁴⁰ was plated and incubated with the experimental CAR T cells at 10:1, 1:1, and 1:10 effector-to-target cell ratios. Tumor-specific T-cell cytotoxicity was measured using the Bright Glo Luciferase Assay System (Promega). Cytotoxic killing was measured as a decrease in luciferase activity and compared to killing of leukemia cells with triton detergent, which was set at 100%. T cells were simultaneously tested for CD19 CAR expression using a CD19 CAR-specific antibody (gift from Novartis) conjugated with R-Phycoerythrin AffiniPure F(ab')₂ Fragment Goat Anti-Human immunoglobulin G, Fcγ Fragment Specific, as well as the negative checkpoint regulators mouse monoclonal anti-human CD279 (PD-1) BV510 (BD Biosciences), mouse monoclonal anti-human CD223 (Lag-3) PerCP-eFluor 710 (eBioscience), and mouse monoclonal anti-human TIM-3 (CD366) BV421 (BD Biosciences). Flow cytometry acquisition was performed with a BD FACSVerser (BD Biosciences), and analysis was done with FlowJo (Treestar, Inc.). The luciferase assays and antibody testing were completed daily over 8 days to evaluate for persistence of CAR expression and T-cell viability among the different CAR T-cell constructs. T cells were counted throughout using the Moxi Z mini automated cell counter (Orflo). Experiments were repeated at

least three times with different batches of mRNA and T-cell donors to ensure accuracy.

Mouse xenograft studies

Studies were performed in 6- to 10-week-old NOD-SCID- $\gamma\text{c}^{-/-}$ (NSG) mice obtained from Jackson Laboratories or bred in-house under an approved protocol and maintained under pathogen-free conditions. Mice were injected via the tail vein with 1×10^6 primary leukemia cells transformed with luciferase (CHP101) in 0.1 mL of sterile phosphate-buffered saline (PBS), as previously described.⁴⁰ After achieving appropriate leukemic burden at 10 days, mice were injected via the tail vein with 2×10^7 CAR T cells in 0.1 mL of sterile PBS. T cells had been transfected with RNA 4 days prior and incubated at 37°C before injection. Mice were then evaluated frequently for persistent leukemia by optical imaging, as previously described.⁴⁰ Animals were closely monitored for the signs of xenogeneic graft-versus-host disease and other toxicity, and all efforts were made to minimize suffering. All animal studies were approved by the Institutional Animal Care and Use Committee of the Children's Hospital of Philadelphia (IAC 15-000232).

Gene expression analysis

To evaluate the CAR T-cell constructs for differences in immune activation following transfection with the various mRNAs, Nanostring RNA sequencing technology (Nanostring Technologies) was utilized to investigate gene expression. CAR T cells made from the experimental mRNA groups were lysed, and RNA was extracted using Quick-RNA Miniprep (Zymo Research) on days 1 and 4 post transfection. Isolated RNA (25–50 ng) was then hybridized with the nCounter PanCancer Immune Profiling Panel, which includes 770 genes involved in immune responses, cell cycle, and function. Gene expression data were then acquired on the nCounter™ Sprint Profiler v3.0 and evaluated using nSolver software (Nanostring Technologies). Gene expression studies were repeated twice with different mRNA batches and T-cell donors to ensure accuracy.

Statistical analysis

Statistical analysis was performed with Prism v7 (GraphPad Software). *In vitro* cytotoxic killing data represent means of triplicate, and comparisons of means were made via a *t*-test. Flow cytometry data were evaluated using mean fluorescence intensity, with confidence intervals generated by FlowJo, and statistical comparison was completed

with a two-way analysis of variance (ANOVA), as well as Fisher's exact test for comparison of cell populations. For *in vivo* data, comparison of radiance was evaluated using a two-way ANOVA for each group on each day.

RESULTS

Transfection of purified and m1Ψ-modified mRNA leads to increased CAR expression in T cells and cytotoxic killing *in vitro*

First, the various mRNA CARs were evaluated for CAR expression and cytotoxic killing efficacy *in vitro* over time. One day after transfection, the addition of purification and/or nucleoside-modification to mRNA induced a 1.5- to 2-fold increase in CAR expression compared to those mRNAs prepared by conventional techniques (Fig. 1A). CAR mean fluorescence intensity (MFI) for mRNA prepared by conventional techniques was 53,563 for day 1 compared to 88,981 for nucleoside modified m1Ψ-mRNA ($p < 0.0001$), 76,296 for purified m1Ψ-mRNA ($p < 0.0001$), and 95,535 for purified U-mRNA ($p < 0.0001$). CAR expression decreased rapidly over the subsequent days, with the purified U-mRNA and purified m1Ψ-mRNA falling to similar expression levels as the original mRNA CAR by day 2, and a slower decline for m1Ψ-

mRNA, which normalized with U-mRNA at day 4. All groups showed a small amount of CAR expression persisting until day 6 post-transfection.

In parallel, the cytotoxic killing potential of the various mRNA CARs was evaluated against Nalm 6 leukemia cell lines *in vitro*. T cells electroporated with purified U-mRNA, m1Ψ-mRNA, and purified m1Ψ-mRNA encoding CARs all showed a twofold increase in cytotoxic killing compared to the conventional, unpurified U-mRNA CAR, with improved efficacy that persisted up to 5 days (Fig. 1B). When evaluated together, the novel CAR mRNAs showed a significant and persistent increase in cytotoxic killing efficacy, despite rapidly decreasing CAR expression (Fig. 1D), suggesting that the improved cytotoxic effect was mediated by additional factors other than improved CAR expression alone. Investigation of proliferative capacity showed the experimental groups containing purified and/or m1Ψ-mRNA CAR T cells doubled in growth ($p < 0.05$) compared to U-mRNA CAR T cells that remained overall stagnant (Fig. 1C).

T cells transfected with m1Ψ-modified or purified mRNA encoding CAR express lower levels of checkpoint regulators

As T cells undergo activation, they express a series of negative checkpoint receptors that by

Figure 1. High expression of chimeric antigen receptor (CAR) and improved cytotoxicity of T cells transfected with nucleoside-modified and purified mRNA CAR. (A) CAR19 expression over time measured in mean fluorescence intensity (MFI), staining for CAR19 with specific antibody. (B) *In vitro* T-cell killing assay. Cytotoxicity measured in comparison to killing of leukemia cells by triton X-100 detergent. (C) Proliferation of CAR T cells measured in cell count from day 1 to day 4 post transfection. (D) CAR expression and cytotoxicity plotted together over time. Data in (A–C) are means $\pm$ 95% confidence intervals (CI) of one experiment. Each experiment was repeated two to four times with similar results. Data in (D) are means $\pm$ 95% CI of three experiments.

binding to their ligands inhibit cell growth and decrease the proliferative capacity of T cells, leading to exhaustion. The first of these receptors to appear is programmed cell death protein 1 (PD-1), which is expressed when the T cell is initially activated.⁴¹ Subsequently, additional markers such as lymphocyte activation gene 3 (Lag-3) and T-cell immunoglobulin mucin-3 (Tim-3) are expressed, and when T cells exhibit two or more of these markers, they are highly susceptible to inhibition and reach the end of their life-span.^{41,42} PD-1 and Lag-3 expression was measured in the mRNA CAR T cells over time after transfection (Fig. 2). Initially, PD-1 and Lag-3 were co-expressed at similar levels on all T-cell groups on day 1, as the shock of electroporation itself activated a proportion of T cells likely via type I interferon responses⁴³ and eIF2 α phosphorylation,⁴⁴ resulting in expression of multiple negative checkpoint regulators. On day 4, after the effect of electric shock subsided, T cells that had been transfected with purified or m1 Ψ -modified CAR mRNA exhibited less dual expression of PD-1 and Lag-3 compared to those transfected with the unpurified U-mRNA (Fig. 2). The proportion of cells with dual expression of PD-1 and Lag-3 was 56.97% when unpurified U-mRNA was used compared to 8.29–15.63% when the purified and/or m1 Ψ -modified mRNA was transfected ($p < 0.0001$). Measurement of Tim-3 showed minimal staining across all groups with similar expression compared to untransfected cells ($p = 0.4391$).

Improved cytotoxic killing *in vivo* by T cells when generated with purified CAR mRNA

To assess anti-leukemic activity *in vivo*, mice injected with primary leukemia were subsequently injected with a single dose of 2×10^7 mRNA CAR T cells, saline, or untransfected T cells as a control. RNA CAR T cells had been transfected 4 days prior to injection and kept incubated at 37°C. Following a single dose of mRNA CAR T cells, leukemia progressed rapidly over the course of 1 month for control animals (Fig. 3A). Mice treated with CAR mRNA generated with unpurified U-mRNA had slightly reduced leukemic growth compared to controls, but they still had a two-log increase in leukemic burden over the course of the month (Fig. 3A). Among the improved CAR mRNA constructs, all three groups showed improvement in leukemic burden compared to both the control groups and U-mRNA CAR T cell-treated group ($p < 0.05$), with the two purified mRNA groups showing the most improvement. The U-mRNA purified CAR T cells as well as the m1 Ψ -mRNA purified CAR T cells were successful in keeping the leu-

kemic burden at its baseline, two orders of magnitude improved from the unpurified U-mRNA CAR T cell and control groups ($p = 0.0138$ and 0.0106 , respectively; Fig. 3A and B).

Distinct activation profile for purified and m1 Ψ -modified mRNA CAR T cells

To investigate the underlying mechanism for the differences in cytotoxicity and negative checkpoint regulator expression in the CAR T cells, genomic expression results were evaluated across a panel of immune and cell function genes after transfection with selected mRNA constructs. Using the nCounter PanCancer Immune Profiling Panel, a heat map representation was created for multiple grouped genes such as those involved in overall cell function, T cell-specific function, encoding cytokines and chemokines (Supplementary Table S1). A pattern emerged showing overall increased expression of numerous genes in the unpurified U-mRNA, with generally decreased expression in both the purified and m1 Ψ -mRNA cohorts (Fig. 4). While the CAR T cells containing m1 Ψ -mRNA segregated with untransfected cells in their pattern of gene activation based on unsupervised clustering analysis, the purified U-mRNA CAR T cells appeared to have a distinct expression profile at a moderate level of gene expression between unpurified U-mRNA and untransfected cells. Type I interferons were downregulated in both the m1 Ψ -mRNA-containing and purified groups compared to U-mRNA-containing T cells (Fig. 4). Among the groups of genes with increased activation in the unpurified U-mRNA T cells included Toll-like receptors (TLR) and the tumor necrosis factor superfamily (TNFSF; Fig. 4). Genes induced in this family in the U-mRNA T cells included pro-apoptotic proteins Fas, TNFSF12, Death receptor 5 (DR5), and tumor necrosis factor receptor superfamily member 10B (TNFRSF10B), as well as genes normally not expressed in T cells including TNFSF15 (Fig. 4). This clustering pattern of over-activation in the unpurified U-mRNA T cells was persistent across profile panels (Fig. 4).

DISCUSSION

While immunotherapy has emerged as a major breakthrough in the treatment of cancer, there remains a continued need for improvement and advancement of the current techniques. In particular, CAR T-cell therapy investigators are actively searching for novel tumor antigens, each with as yet undetermined potential toxicities related to normal tissue expression, which magnifies the need for a transiently expressed CAR that can

Figure 2. Low levels of negative checkpoint regulators on T cells transfected with nucleoside-modified and purified mRNA CAR T cells. Flow cytometry with gating on CD3 and CAR expressing T cells only. Day 1 shows similar values of programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (Lag-3) double-positivity, as the transduction process activates and exhausts a portion of the T-cell population across all transfected groups. On day 4, there are less double-positive T cells in the cohort transfected with m1Ψ-modified and purified mRNA CAR, with T cells showing PD-1 positivity only.

Figure 3. T cells electroporated with purified mRNA encoding CAR show the most efficient killing *in vivo*. **(A)** Leukemia burden measured in bioluminescent imaging over the course of 1 month revealed accelerated tumor growth for controls and mice treated with conventional mRNA CAR. T cells transfected with nucleoside-modified mRNA CAR resulted in one-log reduction of tumor growth, whereas those transfected with purified uridine-containing mRNA CARs achieved two-log reduction in tumor growth, which maintained leukemic burden at baseline. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$. **(B)** Bioluminescent imaging at day 32 showing minimal leukemic burden in animals receiving T cells generated with purified mRNA CAR compared to other groups.

provide both an evaluation for efficacy against tumor, as well as a transient mechanism to evaluate for toxicity. Several groups have investigated the use of alternate means to create a transient CAR, such as incorporating the inducible Caspase 9 suicide gene. However, prior work using this model in T cells has shown re-expansion of the T-cell population over time⁴⁵ and failure of the suicide mechanism,⁴⁶ as it is difficult to ensure that all T cells have the incorporated gene or that the agent given to activate the suicide gene reaches all cells. As a direct consequence, it is difficult to assure that all CAR T cells would truly be eliminated using this approach. mRNA is unique in its ability to offer a truly transient expression of CAR. However, prior work has shown only modest efficacy with clear limitations when applied across multiple tumor types.^{29,30,47} This report demonstrates that elimination of dsRNA contaminants by introducing a digestion with RNase III resulted in pure single-stranded CAR mRNA, which when transfected to T cells led to robust improvement in the efficacy of tumor killing, both *in vivo* and *in vitro*. With continued transient expression, this new CAR mRNA is an improved platform for novel investigations in CAR therapy as well as other therapeutic applications of mRNA.

The improved efficacy that was found *in vivo* and *in vitro* throughout these experiments exceeded that expected in the context of the CAR expression profile. While it was possible to show initial improved CAR expression on the surface of T cells

using these new mRNA techniques, CAR expression rapidly declined to a level comparable to the conventional CAR construct, as the T cells proliferated and mRNA was diluted and degraded. However, despite similar CAR expression over time, the new mRNA constructs offered robust improved potency. This increase in potency was attributable to two findings. First, the updated mRNA resulted in an increased number of T cells due to increased proliferative capacity, resulting in rapid decrease of CAR expression and a sheer increase in volume of effector-to-target cells. In this context, cytotoxicity was enhanced. In addition, a decrease in the level of negative checkpoint receptors was also observed in T cells transfected with the improved mRNA constructs. Those T cells appeared to be activated without overstimulation to the point of expression of multiple negative checkpoint receptors, enabling the T cells to proliferate and extending their cytotoxicity through cytokine release and directed killing compared to those generated by prior methods. This result is supported by the genomic expression profiling, which reveals an over-activation of U-mRNA containing T cells compared to m1Ψ and purified mRNA containing T cells. Interestingly, a different gene expression profile emerged for the two purified constructs, U and m1Ψ- mRNA, which was surprising, as the two purified constructs performed similarly *in vivo*. Most likely, this difference in gene expression is related to the broad array of genes investigated in the panel, with only a select few

Figure 4. Gene expression profiles of T cells reveal differential pattern of activation by mRNA CAR constructs. T-cell function, interleukins, toll-like receptors, and tumor necrosis factor superfamily RNA sequencing data are displayed at day 4 after transfection with CAR mRNA. Unpurified U-mRNA transfected cells show the highest expression across all profiles. Heat maps include normalized RNA sequencing data and are scaled to give all genes equal variance. *Orange* represents high expression; *blue* represents low expression. The experiment was repeated with a different batch of mRNA and T-cell donor with identical clustering.

genes being most important in determining T-cell cytotoxic function. Pattern recognition receptors (PRR) activation including TLR (Fig. 4) appeared to be similar among the purified constructs, making these a likely candidate for the enhanced efficacy. Future studies will continue to investigate these genes and opportunities for maximizing T-cell cytotoxicity, such as the use of co-delivery of PRR inhibitors.

The *in vitro* and *in vivo* model showed that purification alone of the CAR mRNA was sufficient to achieve maximal T-cell cytotoxicity. During purification, dsRNA, the major contaminant in IVT mRNA, was eliminated by dsRNA-specific RNase III digestion. DsRNA, which activates innate immune receptors, can lead to type I interferon secretion and inhibition of translation.³⁵ Similarly, unmodified mRNA also activates the innate immune system, as immune cells detect unmodified nucleosides in RNA.³⁴ The gene expression data showed decreased type I interferon expression across all of the purified mRNA constructs. In the *in vitro* studies presented here, as well as in a prior investigation where purified, dsRNA-free IVT RNAs were tested, removal of contaminants led to improved translation, but with an additional improvement when the purified mRNA contained modified nucleosides.³⁵ In the present study, both purified U-mRNA and purified m1Ψ-mRNA performed equally well *in vivo* compared to slightly decreased efficacy of m1Ψ-mRNA alone. This discrepancy is likely due to the use of electroporation for delivery of the mRNA into T cells. Kirschman *et al.*⁴⁸ recently showed that when using electroporation for mRNA delivery, the nucleoside-modified and unmodified mRNAs translated equally, which is in contrast to transfection of formulated mRNA where modifications in mRNAs play a significant role in improving their translation. Unlike formulated mRNA, the electroporated naked mRNA enters directly into the cytoplasm, thus avoiding endosomally located TLR7 and TLR8, both of which are activated by uridine-containing ssRNA or uridine, respectively.^{49,50} Although the dsRNA contaminants present in the electroporated mRNA also bypass the endosome and its receptor, TLR3, there are many different types of dsRNA sensors and effectors in the cytoplasm such as RIG-I, MDA5, PKR, and OAS.⁵¹ Activation of these dsRNA-dependent proteins induces interferon response and inhibition of protein synthesis. Removal of dsRNA with RNaseIII treatment thus contributed to the superior performance of the T cells electroporated with purified mRNA CAR.

The impact of purification with RNase III on the translational performance of IVT mRNA has never been reported. To the authors' knowledge, this is the first report in which T cells were transfected *ex vivo* with purified and nucleoside-modified IVT mRNA and then characterized *in vivo*. Prior studies have used pseudouridine-containing IVT mRNA to generate induced pluripotent stem cells⁵² and to transfect *ex vivo* into mesenchymal stem cells that were subsequently evaluated *in vivo*.⁵³ In these studies, Ψ-mRNA was superior to U-mRNA,^{52,53} most likely because the IVT mRNAs were formulated prior to transfection. In recent studies, m1Ψ-modified and purified IVT mRNA was formulated and then injected into mice directly to generate T cell-engaging bi-specific antibodies, and no adverse reactions were detected.⁵⁴ This report is the first to apply purified and nucleoside-modified IVT mRNA in chimeric antigen receptor technology.

As new mRNA CAR clinical trials are currently underway for both hematologic and solid tumor malignancies (NCT01837602, NCT03060356, and NCT02624258), incorporation of the present findings into the manufacturing of mRNA CAR T cells becomes even more paramount to achieve the aims of the trials. This work demonstrates that utilizing purification can vastly improve the efficacy of mRNA CAR T cells and reduce the overstimulation of T cells during the electroporation process. It is anticipated that this purification technique will be rapidly translatable to clinical trials and large-scale applications, as well as enhancing the platform for evaluating novel chimeric antigens in both preclinical and clinical testing.

ACKNOWLEDGMENTS

Research Supported by St. Baldrick's Stand Up To Cancer Pediatric Dream Team Translational Research Grant (SU2C-AACR-DT-27-17; J.B.F. and A.C.R.). Stand Up to Cancer is a division of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the Scientific Partner of SU2C. This work was also supported by the St. Baldrick's Foundation and the Gabrielle's Angels Foundation for Cancer Research (D.M.B.).

AUTHOR DISCLOSURE

S.A.G. has a consulting agreement with and receives research funding from Novartis. K.K. is currently employed by BioNTech RNA Pharmaceuticals. None of the other authors have any conflicts of interest to disclose.

REFERENCES

1. Eshhar Z. Tumor-specific T-bodies: towards clinical application. *Cancer Immunol Immunother* 1997;45:131–136.
2. Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. *Proc Natl Acad Sci U S A* 1993;90:720–724.
3. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. *Adv Immunol* 2006;90:51–81.
4. Kochenderfer JN, Feldman SA, Zhao Y, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. *J Immunother* 2009;32:689–702.
5. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *N Engl J Med* 2011;365:725–733.
6. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *N Engl J Med* 2013;368:1509–1518.
7. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. *N Engl J Med* 2014;371:1507–1517.
8. Ahmed N, Brawley VS, Hegde M, et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. *J Clin Oncol* 2015;33:1688–1696.
9. Katz SC, Burga RA, McCormack E, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. *Clin Cancer Res* 2015;21:3149–3159.
10. Feng K, Guo Y, Dai H, et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. *Sci China Life Sci* 2016;59:468–479.
11. Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. *J Clin Oncol* 2006;24:e20–22.
12. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. *J Clin Invest* 2008;118:3132–3142.
13. Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for Wiskott-Aldrich syndrome—long-term efficacy and genotoxicity. *Sci Transl Med* 2014;6:227ra233.
14. Barrett DM, Zhao Y, Liu X, et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. *Hum Gene Ther* 2011;22:1575–1586.
15. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood* 2014;124:188–195.
16. Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. *Cancer Discov* 2016;6:664–679.
17. Singh N, Hofmann TJ, Gershenson Z, et al. Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. *Cytotherapy* 2017;19:867–880.
18. Gust J, Hay KA, Hanafi L-A, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. *Cancer Discov* 2017;7:1404–1419.
19. Morgan RA, Chinnsamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. *J Immunother* 2013;36:133–151.
20. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. *Mol Ther* 2010;18:843–851.
21. Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. *Blood* 2013;122:863–871.
22. Cameron BJ, Gerry AB, Dukes J, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. *Sci Transl Med* 2013;5:197ra103.
23. Lamers CH, Sleijfer S, van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. *Mol Ther* 2013;21:904–912.
24. Singh N, Liu X, Hult J, et al. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma. *Cancer Immunol Res* 2014;2:1059–1070.
25. Zhao Y, Moon E, Carpenito C, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. *Cancer Res* 2010;70:9053–9061.
26. Barrett DM, Singh N, Porter DL, et al. Chimeric antigen receptor therapy for cancer. *Annu Rev Med* 2014;65:333–347.
27. Panjwani MK, Smith JB, Schutsky K, et al. Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma. *Mol Ther* 2016;24:1602–1614.
28. Tasian SK, Kenderian SS, Shen F, et al. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. *Blood* 2017;129:2395–2407.
29. Schutsky K, Song DG, Lynn R, et al. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. *Oncotarget* 2015;6:28911–28928.
30. Yoon SH, Lee JM, Cho HI, et al. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model. *Cancer Gene Ther* 2009;16:489–497.
31. Sahin U, Kariko K, Tureci O. mRNA-based therapeutics—developing a new class of drugs. *Nat Rev Drug Discov* 2014;13:759–780.
32. Kariko K, Muramatsu H, Welsh FA, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. *Mol Ther* 2008;16:1833–1840.
33. Anderson BR, Muramatsu H, Jha BK, et al. Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L. *Nucleic Acids Res* 2011;39:9329–9338.
34. Kariko K, Buckstein M, Ni H, et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. *Immunity* 2005;23:165–175.
35. Kariko K, Muramatsu H, Ludwig J, et al. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. *Nucleic Acids Res* 2011;39:e142.
36. Anderson BR, Muramatsu H, Nallagatla SR, et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. *Nucleic Acids Res* 2010;38:5884–5892.
37. Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. *Proc Natl Acad Sci U S A* 2009;106:3360–3365.
38. Pardi N, Muramatsu H, Weissman D, et al. *In vitro* transcription of long RNA containing modified nucleosides. *Methods Mol Biol* 2013;969:29–42.
39. Meis J, Person A, Chin C, et al. Making and using *in vitro*-synthesized ssRNA for introducing into mammalian cells to induce a biological or biochemical effect. *EU patent 2,798,064* 2016.
40. Barrett DM, Seif AE, Carpenito C, et al. Non-invasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. *Blood* 2011;118:e112–117.
41. Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. *Immunol Rev* 2008;224:141–165.

42. Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3—potential mechanisms of action. *Nat Rev Immunol* 2015;15:45–56.
43. Huerfano S, Ryabchenko B, Forstova J. Nucleofection of expression vectors induces a robust interferon response and inhibition of cell proliferation. *DNA Cell Biol* 2013;32:467–479.
44. Anderson BR, Kariko K, Weissman D. Nucleofection induces transient eIF2alpha phosphorylation by GCN2 and PERK. *Gene Ther* 2013;20:136–142.
45. Zhou X, Di Stasi A, Tey SK, et al. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. *Blood* 2014;123:3895–3905.
46. Qasim W, Zhan H, Samarasinghe S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. *Sci Transl Med* 2017;9.
47. Singh N, Barrett DM, Grupp SA. Roadblocks to success for RNA CARs in solid tumors. *Oncoimmunology* 2014;3:e962974.
48. Kirschman JL, Bhosle S, Vanover D, et al. Characterizing exogenous mRNA delivery, trafficking, cytoplasmic release and RNA-protein correlations at the level of single cells. *Nucleic Acids Res* 2017;45:3113.
49. Tanji H, Ohto U, Shibata T, et al. Toll-like receptor 8 senses degradation products of single-stranded RNA. *Nat Struct Mol Biol* 2015;22:109–115.
50. Zhang Z, Ohto U, Shibata T, et al. Structural analysis reveals that Toll-like receptor 7 is a dual receptor for guanosine and single-stranded RNA. *Immunity* 2016;45:737–748.
51. Chen N, Xia P, Li S, et al. RNA sensors of the innate immune system and their detection of pathogens. *IUBMB Life* 2017;69:297–304.
52. Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. *Cell Stem Cell* 2010;7:618–630.
53. Levy O, Zhao W, Mortensen LJ, et al. mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. *Blood* 2013;122:e23–32.
54. Stadler CR, Bahr-Mahmud H, Celik L, et al. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. *Nat Med* 2017;23:815–817.

Received for publication July 9, 2018;
accepted after revision July 13, 2018.

Published online: July 18, 2018.